Selective α v β 3 integrin blockade potently limits neointimal hyperplasia and lumen stenosis following deep coronary arterial stent injury : Evidence for the functional importance of integrin α v β 3 and osteopontin expression during neointima formation

Cardiovascular Research

Volumn 36, Issue 3, 1997, Pages 408-428

  Srivatsa, S Sanjay ^a   Fitzpatrick, Lorraine A ^a   Tsao, Peter W ^b   Reilly, Thomas M ^b   Holmes Jr , David R ^a   Schwartz, Robert S ^a   Mousa, Shaker A ^b  

^a MAYO CLINIC   (United States)

^b DUPONT COMPANY   (United States)

Author keywords

Adhesion; Alpha v beta 3; Integrins; Migration; Porcine coronary; Remodeling; Restenosis; Stent

Indexed keywords

ARGINYLGLYCYLASPARTIC ACID; INTEGRIN; OSTEOPONTIN; UNCLASSIFIED DRUG; VITRONECTIN; XJ 735;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY INJURY; ARTERY INTIMA PROLIFERATION; ARTICLE; CELL ADHESION; CELL MIGRATION; CONTROLLED STUDY; CORONARY ARTERY; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; GENE EXPRESSION; HEART MUSCLE REVASCULARIZATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INJURY SCALE; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL; RESTENOSIS; STENT; SWINE; VASCULAR SMOOTH MUSCLE;

ANIMALS; CELL ADHESION; CELL MOVEMENT; CORONARY DISEASE; CORONARY VESSELS; ENDOTHELIUM, VASCULAR; FIBRINOGEN; OSTEOPONTIN; PEPTIDES, CYCLIC; PROTEIN BINDING; RECEPTORS, VITRONECTIN; RECURRENCE; SIALOGLYCOPROTEINS; STENTS; SWINE; VITRONECTIN;

EID: 0031456703     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(97)00184-3     Document Type: Article

References (58)

1. Hynes RO Integrins: versatility, modulation, and signaling in cell adhesion. Cell. 69:1992;11-25.
2. Luscinskas FW, Lawler J Integrins as dynamic regulators of vascular function. FASEB J. 8:1994;929-938.
3. Clyman RI, Mauray F, Kramer RH Beta 1 and beta 3 integrins have different roles in the adhesion and migration of vascular smooth muscle cells on extracellular matrix. Exp Cell Res. 200(2):1992;272-284.
4. Shattil SJ Function and regulation of the beta 3 integrins in hemostasis and vascular biology. Thromb Hemostas. 74(1):1995;149-155.
5. Cheresh DA Human endothelial cells synthesize and express an Arg-Gly-Asp- directed adhesion receptor involved in attachment to fibrinogen and von Willebrand factor. Proc Natl Acad Sci USA. 84(84):1987;6471-6475.
6. Murphy JF, Bordet JC, Wyler B, Rissoan M-C, Chomarat P, DeFrance T, Miossec P, McGregor JL The vitronectin receptor (alpha v beta 3) is implicated, in cooperation with P-selectin and platelet-activating factor, in the adhesion of monocytes to activated endothelial cells. Biochem J. 304:1994;537-542.
7. Huang S, Endo RI, Nemerow GR Upregulation of integrins alpha v beta 3 and alpha v beta 5 on human monocytes and T lymphocytes facilitates adenovirus-mediated gene delivery. J Virol. 69(4):1995;2257-2263.
8. Stern M, Savill J, Haslett C Human monocyte-derived macrophage phagocytosis of senescent eosinophils undergoing apoptosis. Am J Pathol. 149(3):1996;911-921.
9. Hall SE, Savill JS, Henson PM, Haslett C Apoptotic neutrophils are phagocytosed by fibroblasts with participation of the fibroblast vitronectin receptor and involvement of a mannose/fucose-specific lectin. J Immunol. 153(7):1994;3218-3227.
10. Albelda SM, Buck CA. Integrins and other cell adhesion molecules. FASEB J. 1990;4:2868-2880.
11. Yue T-L, McKenna PJ, Ohlstein EH, Farach-Carson MC, Butler WT, Johanson K, McDevitt P, Feuerstein GZ, Stadel JM Osteopontin-stimulated vascular smooth muscle migration is mediated by β3 integrin. Exp Cell Res. 214(459):1994;459-464.
12. Liaw L, Skinner MP, Raines EW, Ross R, Cheresh DA, Schwartz SM The adhesive and migratory effects of osteopontin are mediated via distinct cell surface integrins.Role of alpha v beta 3 in smooth muscle cell migration to osteopontin in vitro. J Clin Invest. 95:1995;713-724.
13. Coller BS, Seligsohn U, West SM, Scuder LE, Norton KJ Platelet fibrinogen and vitronectin in Glanzmann thrombasthenia: evidence consistent with specific roles for glycoprotein IIb/IIIa and alpha v beta 3 integrins in platelet protein trafficking. Blood. 78:1991;2603-2610.
14. Brooks PC, Clark RA, Cheresh DA Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science. 264(5158):1994;569-571.
15. Horton MA, Taylor L, Arnett TR, Helfrich MH Arg-Gly-Asp (RGD) peptides and the anti-vitronectin receptor antibody 23C6 inhibit dentine resorption and cell spreading by osteoclasts. Exp Cell Res. 195:1991;368-375.
16. Savill J, Dransfield I, Hogg N, Haslett N. Vitronectin receptor-mediated phagocytosis of cells undergoing apoptosis. Nature 1990;343:170-173.
17. Seftor REB, Seftor EA, Gehlsen KR, Stetler-Stevenson WG, Brown PD, Ruoslahti E, Hendrix MJ Role of the avb3 integrin in human melanoma cell invasion. Proc Natl Acad Sci USA. 89:1992;1557-1561.
18. Liaw L, Almeida M, Hart CE, Schwartz SM, Giachelli CM Osteopontin promotes vascular cell adhesion and spreading and is chemotactic for smooth muscle cells in vitro. Circ Res. 74(2):1994;214-224.
19. Choi ET, Engel L, Callow AD, Sun S, Trachtenberg J, Santoro S, Ryan US Inhibition of neointimal hyperplasia by blocking alpha v beta 3 integrin with a small peptide antagonist GpenGRGDSPCA. J Vasc Surgery. 19(1):1994;125-134.
20. Janat MF, Argraves WS, Liau G Regulation of vascular smooth muscle cell integrin expression by transforming growth factor beta1 and by platelet-derived growth factor-BB. J Cell Physiol. 151(3):1992;588-595.
21. Le Breton H, Rabbani R, Plow EF, Mousa SA, Lincoff AM, Forudi F, Topol EJ. The role of integrins αIIb/β3 (glycoprotein IIb/IIIa), and αvβ3 (the vitronectin receptor) in a guinea-pig model of restenosis. Circul Suppl 1996;94(8):1-517.
22. Matsuno H, Stassen JM, Vermylen J, Deckmyn H Inhibition of integrin function by a cyclic RGD-containing peptide prevents neointima formation. Circulation. 90(5):1994;2203-2206.
23. Slepian MJ, Massia SP. Preferential antagonism of β3 versus β1 integrin-matrix interactions in vivo limits neointimal hyperplasia following arterial balloon injury. Circulation 1994;90 (4):Abstr 449:1-85.
24. Lundgren CH, Sawa H, Fujii S Inhibition of neointimal hyperplasia after balloon injury by local delivery of a cyclic arginine-glycine-aspartic acid peptide targeting vitronectin receptor [abstract]. J Am Coll Cardiol. 25:1995;83A.
25. Smith JW, Ruggeri ZM, Kunicki TJ, Cheresh DA Interactions of integrins αvβ3 and glycoprotein IIb-IIIa with fibrinogen. J Biol Chem. 265:1990;12267-12271.
26. Pytela R, Pierschbacher MD, Ginsberg MH, Plow EF, Ruoslahti E Platelet membrane glycoprotein IIb/IIIa: member of a family of Arg-Gly-Asp specific adhesion receptors. Science. 231:1986;1559-1562.
27. Topol EJ, Califf RM, Weisman HF, Ellis SG, Tcheng JE, Worley S Randomized trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. Lancet. 343:1994;881-886.
28. Ferrell M, Fuster V, Gold HK, Chesebro JH A dilemma for the 1990s: choosing an appropriate experimental model for the prevention of restenosis. Circulation. 85:1992;1630-1631.
29. Srivatsa S, Edwards WDE, Simari RD, Holmes DR, Schwartz RS Coronary restenosis: development of neointimal hyperplasia in experimental vascular injury. J Invasive Cardiol. 5(9):1993;334-344.
30. Fischman DL, Leon MB, Baim DS, Schatz RA, Savage MP, Penn I A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary disease. N Engl J Med. 331:1994;496-501.
31. Serruys PW, de Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G, et al. A comparison of balloon-expandable stent implantation with balloon angioplasty in patients with coronary disease. N Engl J Med 1994;331:489-495.
32. Hoffman R, Mintz GS, Dussaillant GR, et al. Patterns and mechanisms of in-stent restenosis: A serial intravsacular ultrasound study. Circulation 1996;94:1247-1254.
33. Mousa S, Forsythe M, Lorelli W, et al. Discovery of a novel nonpeptide antiplatelet GPIIb/IIIa receptor antagonist, DMP 754: Receptor binding affinity and specificity. Coronary Artery Disease 1996;7:767-774.
34. Carter-Grinstead W, Rodgers GP, Mazur W, et al. Comparison of three porcine restenosis models: the relative importance of hypercholesterolemia, endothelial abrasion, and stenting. Coronary Artery Disease 1994;5:425-434.
35. Schwartz R.S., Huber K.C., Murphy J.G., Edwards W.D.E., Camrud A.R., Vlietstra R., Holmes D.R. Jr. Restenosis and the proportional neointimal response to coronary artery injury: Results in a porcine model. J Am Coll Cardiol. 19(2):1992;267-274.
36. Schwartz RS, Murphy JG, Edwards WDE, Camrud AR, Vlietstra R, Holmes DR Jr. Restenosis after balloon angioplasty: A practical proliferative model in porcine coronary arteries. Circulation. 82:1990;2190-2200.
37. Brooks PC, Montgomery AM, Rosenfeld M, Reisfeld RA, Hu T, Klier G, Cheresh DA Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell. 79(7):1994;1157-1164.
38. Liaw L, Lindner V, Schwartz SM, Chambers AF, Giachelli CM Osteopontin and beta 3 integrin are coordinately expressed in regenerating endothelium in vivo and stimulate Arg-Gly-Asp dependent endothelial migration in vitro. Circ Res. 77(4):1995;665-672.
39. Coller BS A new nurine monoclonal antibody reports an activation dependent change in the confirmation and/or microenvironment of the platelet GPIIb/IIIa complex. J Clin Invest. 76:1985;101-108.
40. Peter K, Schwarz M, Kohler B, Bauer S, Nordt T, Bode, C. The monoclonal antibody c7E3 binds to Mac-1 on resting and stimulated monocytes, and thus blocks fibrinogen- mediated monocyte aggregation and adhesion [abstract]. Abstracts submitted to the Council on Arteriosclerosis for the 69th Scientific Sessions of the American Heart Association. Circulation (A8262):109.
41. Tcheng JE, Harrington RA, Kottke-Marchant K, et al. for the IMPACT investigators. Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker Integrelin in elective coronary intervention. Circulation 1995;91:2151-2157.
42. Reverter J.C., Beguin S., Kessels H., Kumar R., Hemker H.C., Coller B.S. Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. J Clin Invest. 98(3):1996;863-874.
43. Schwartz SM. How vessels narrow. Z Kardiol 1995;84 (Suppl 4):129-135.
44. Schwartz RS, Holmes DR, Topol EJ The restenosis paradigm revisited: An alternative proposal for cellular mechanisms. J Am Col Cardiol. 20(5):1992;1284-1293.
45. Shi Y, Pieniek M, O'Brien J, Mannion JD, Zalewski A Adventitial remodeling after coronary arterial injury. Circulation. 93(2):1996;340-348.
46. Scott NA, Cipolla GD, Ross CE, Dunn B, Martin FH, Simonet L, Wilcox JN Identification of a potential role for the adventitia in vascular lesion formation after balloon overstretch injury of porcine coronary arteries. Circulation. 93(12):1996;2178-2187.
47. Clark RAF, Tonnesen MG, Gailit J, Cheresh DA Transient functional expression of αvβ3 on vascular cells during wound repair. Am J Pathol. 148(5):1996;1407-1421.
48. Senger DR, Ledbetter SR, Claffey KP, Papadopoulos-Sergiou A, Perruzzi CA, Detmar M Stimulation of endothelial cell migration by vascular permeability factor/vascular endothelial growth factor through cooperative mechanisms involving the αvβ3 integrin, osteopontin, and thrombin. Am J Pathol. 149(1):1996;293-305.
49. Giachelli CM, Schwartz SM, Liaw L Molecular and cellular biology of osteopontin: potential role in cardiovascular disease. Trends Cardiovasc Med. 5(3):1995;88-95.
50. Giachelli CM, Bae N, Almeida M, Denhardt DT, Schwartz SM Osteopontin is elevated during neointima formation in rat arteries and is a novel component of human atherosclerotic plaques. J Clin Invest. 92:1993;1686-1696.
51. Senger DR, Perruzzi CA, Papadopoulos-Sergiou A, Van de Water L Adhesive properties of osteopontin: regulation by a naturally occurring thrombin-cleavage site in close proximity to the GRGDS cell-binding domain. Mol Biol Cell. 5(5):1994;565-574.
52. Shimokawa H, Ito A, Fukumoto Y, et al. Chronic treatment with interleukin-1 beta induces coronary intimal lesions and vasospastic responses in pigs in vivo. The role of platelet-derived growth factor. J Clin Invest 1996;97:769-776.
53. Suchiro K, Smith JW, Plow EF The ligand recognition specificty of β3 integrins. J Biol Chem. 271(17):1996;10365-10371.
54. Luna J, Tobe T, Mousa SA, Reilly TM, Campochiaro PA Antagonists of integrin alpha v beta 3 inhibit retinal neovascularization in a murine model. Lab Invest. 75(4):1996;563-573.
55. Brooks PC, Stromblad S, Klemke R, Visscher D, Sarkar FH, Cheresh DA Anti-integrin αvβ3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest. 96:1995;1815-1822.
56. Andersen HR, Maeng M, Thorwest M, Falk E Remodeling rather than neointimal formation explains luminal narrowing after deep vessel wall injury: Insights from a porcine coronary restenosis model. Circulation. 93(9):1996;1716-1724.
57. Edelman ER, Roger CS. Hoop dreams: Stents without restenosis. Circulation 1996;94:1199-1202.
58. Buck CA What's potentially more effective than a roto-rooter and less toxic than drano? Anti-adhesion mimetics! J Clin Invest. 95:1995;2431-2432.